Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide versus best supportive care for prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplant
2016-002004-10Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Aug 2016
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of defibrotide in hepatic veno-occlusive disease (HVOD), sponsored by Jazz Pharmaceuticals plc. Started Aug 2016; status: completed.
02
Drugs
defibrotide
03
Conditions
hepatic veno-occlusive disease (HVOD)
Beyond the preview
Go deeper on 2016-002004-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002004-10.